Last updated: September 5, 2026
Amlodipine besylate/benazepril hydrochloride is a mature, genericized fixed-dose combination used for hypertension. The branded product, Lotrel, no longer has meaningful U.S. exclusivity, and competition is driven by low-cost generic supply rather than innovation. Financial value has shifted from the original brand owner to generic manufacturers, wholesalers, pharmacies, and health plans. Public company filings generally do not disclose product-level revenue for the combination.
What is amlodipine besylate and benazepril hydrochloride?
Amlodipine besylate/benazepril hydrochloride combines a dihydropyridine calcium-channel blocker with an angiotensin-converting enzyme inhibitor.
| Attribute |
Amlodipine besylate |
Benazepril hydrochloride |
| Drug class |
Calcium-channel blocker |
ACE inhibitor |
| Primary effect |
Relaxes vascular smooth muscle |
Reduces angiotensin II formation |
| Main use |
Hypertension |
Hypertension |
| Combination rationale |
Lowers blood pressure through vasodilation |
Adds renin-angiotensin system blockade |
| Administration |
Oral, once daily |
Oral, once daily in combination |
| Common U.S. brand |
Norvasc as monotherapy |
Lotensin as monotherapy |
| Combination brand |
Lotrel |
Lotrel |
The combination is approved for patients whose blood pressure is not adequately controlled with either component alone, or for patients who are likely to require multiple antihypertensive agents. The FDA labeling provides five strengths, including 5/10 mg, 10/20 mg and 10/40 mg combinations, expressed as amlodipine/benazepril equivalents.[1]
What is the FDA regulatory status of Lotrel?
Lotrel was approved by the FDA as a new drug application for hypertension. The product is no longer protected by meaningful U.S. regulatory exclusivity, and multiple abbreviated new drug applications have supported generic entry.
The product’s commercial position is now that of a mature prescription generic:
| Regulatory factor |
Current market implication |
| New drug approval |
Established safety and efficacy record |
| Regulatory exclusivity |
Expired |
| ANDA availability |
Generic competition |
| Biosimilar pathway |
Not applicable because the product is a small molecule |
| Prescription status |
Prescription-only |
| Orange Book role |
Identifies approved reference product and listed patents, if any |
| Brand economics |
Limited unless supported by contracting or residual brand loyalty |
The FDA Orange Book remains the controlling source for current reference-product, patent-listing and therapeutic-equivalence information.[2] FDA labeling identifies Lotrel as a combination product containing amlodipine besylate and benazepril hydrochloride.[1]
When did amlodipine/benazepril lose exclusivity?
The combination lost practical market exclusivity after the expiration of its original regulatory and patent protections and the approval of generic equivalents. The relevant commercial conclusion is clear: generic substitution has been available for years, and the product is not an active exclusivity asset in the United States.
Exclusivity timeline
| Period |
Market event |
Commercial effect |
| 1990s |
Lotrel introduced in the U.S. |
Brand-led pricing and promotion |
| Late 1990s to early 2000s |
Combination and component patent protection matured |
Potential generic-entry planning |
| Mid-2000s onward |
Generic approvals and substitution expanded |
Brand share and price declined |
| Current market |
Mature generic category |
Low unit economics and contracting pressure |
Patent expiration dates for individual historical patents can differ from the date on which commercial generic entry became practical. Patent term adjustments, pediatric exclusivity, Paragraph IV litigation and settlement terms can affect timing. Current Orange Book records should be used for any transaction, litigation or launch decision.[2]
What patents protect amlodipine besylate and benazepril hydrochloride?
The core molecules are old small-molecule antihypertensive agents. Their primary composition-of-matter patents have expired. Any remaining intellectual-property value would be more likely to arise from a narrow formulation, dosage, manufacturing or method-of-use claim than from the active ingredients themselves.
Patent categories
| Patent category |
Relevance today |
| Amlodipine composition of matter |
Expired |
| Benazepril composition of matter |
Expired |
| Fixed-dose combination |
Historical protection; no current broad exclusivity expected |
| Tablet formulation |
Potentially narrow and difficult to monetize after generic entry |
| Manufacturing process |
May create operational know-how but rarely blocks all generic suppliers |
| Method of treatment |
Limited value where hypertension treatment is well established |
| Device or delivery system |
Generally not material for standard oral tablets |
The commercial patent estate is weak compared with newer branded cardiovascular products. A generic manufacturer may still need to address listed patents through a Paragraph IV certification, a section viii statement or a certification that the patent has expired. A patent listing does not itself establish enforceability or market-blocking power.
How many patents cover the Lotrel reference product?
The answer depends on the date and version of the Orange Book record. Historical listed patents may have expired, been delisted, or ceased to create a meaningful commercial barrier. The number of listed patents should not be confused with the number of enforceable patents capable of delaying a generic launch.
For diligence purposes, the relevant questions are:
- Is the patent currently listed for the reference product?
- Has the patent expired, including any patent-term adjustment?
- Does the claim cover the approved product or only a narrow process?
- Has a generic applicant filed a Paragraph IV certification?
- Was litigation filed within the statutory 45-day period?
- Does a settlement impose a launch restriction beyond the patent’s apparent expiry?
The FDA Orange Book and Federal Court records are the appropriate sources for this analysis.[2,3]
Have generic manufacturers challenged Lotrel patents under Paragraph IV?
Generic entry has occurred, which indicates that historical patent barriers no longer prevent broad competition. Paragraph IV activity may have occurred during the original generic-entry period, but the current commercial question is whether any enforceable listed patent remains capable of delaying an ANDA applicant.
A Paragraph IV certification alleges that a listed patent is invalid, unenforceable or not infringed. If the brand holder sues within 45 days, FDA approval may be subject to a statutory stay of up to 30 months, subject to court and regulatory developments.[4]
For a mature product such as amlodipine/benazepril, Paragraph IV risk has largely transitioned from a strategic exclusivity issue to a historical litigation issue. New entrants are more likely to compete on manufacturing cost, wholesaler access, pharmacy contracts and supply reliability.
What patent litigation affects amlodipine and benazepril?
No broad, active patent dispute is generally associated with the mature U.S. market for the standard amlodipine/benazepril tablet. Historical litigation should still be reviewed before acquiring rights, launching a product or relying on a particular patent certification.
Relevant litigation categories include:
- ANDA infringement actions involving fixed-dose tablets.
- Challenges to combination-product patents.
- Disputes over formulation or dissolution claims.
- Manufacturing-process claims.
- Declaratory-judgment actions involving generic launch rights.
- Contract disputes involving authorized generic supply.
Court records should be searched by the reference product, active ingredients, NDA number and patent number. FDA approval records alone do not establish whether a patent dispute existed or was settled.[2,3]
What generic launch risks exist for amlodipine/benazepril?
Generic launch risk is high because the product is already genericized and the clinical technology is mature. The risk is not primarily whether a generic can enter. It is whether a new entrant can earn sustainable margin.
Principal competitive risks
| Risk |
Effect on a new entrant |
| Multiple approved suppliers |
Reduces pricing power |
| Pharmacy benefit substitution |
Accelerates volume migration to lowest-cost suppliers |
| Wholesaler concentration |
Raises access barriers |
| Formulation similarity |
Limits product differentiation |
| Low retail price |
Makes compliance and quality investments harder to recover |
| Supply interruptions |
Create short-term opportunities but not durable exclusivity |
| Rebate and contract competition |
Transfers economics from manufacturers to payers and channels |
The most attractive launch scenario is usually a supply-constrained market in which an entrant receives preferred pharmacy or wholesaler placement. The least attractive scenario is a fully supplied market with several approved ANDAs and aggressive purchasing contracts.
What formulations are protected by patents?
The standard product is an immediate-release oral tablet. Amlodipine/benazepril does not have the formulation complexity associated with inhaled products, long-acting injectables, transdermal systems or modified-release biologics.
Potential formulation claims could address:
- Tablet composition.
- Excipients.
- Dissolution characteristics.
- Stability.
- Manufacturing sequence.
- Particle size or salt handling.
- Packaging and moisture protection.
These claims are usually narrower than composition-of-matter patents. They may support a limited litigation position but are unlikely to preserve broad market exclusivity after the active ingredients and therapeutic combination are established.
Is there biosimilar risk for amlodipine/benazepril?
No. Biosimilar risk does not apply because amlodipine besylate and benazepril hydrochloride are chemically synthesized small molecules, not biologics. The relevant competitive threat is generic substitution under the ANDA pathway.
This distinction affects the market structure:
| Feature |
Amlodipine/benazepril |
Biologic product |
| FDA competition pathway |
ANDA |
Biosimilar BLA |
| Interchangeability issue |
Generic therapeutic equivalence |
May require interchangeable designation |
| Manufacturing complexity |
Conventional oral solid dose |
Biologic cell-line and process controls |
| Patent litigation |
ANDA and Hatch-Waxman |
Biologics Price Competition and Innovation Act |
| Price erosion |
Usually rapid after generic entry |
Often slower and contract-dependent |
What is the financial trajectory of Lotrel and its generic market?
The financial trajectory has followed the standard lifecycle for an older combination antihypertensive:
- Launch phase: Brand pricing, physician promotion and expansion of combination use.
- Maturity phase: Stable prescription demand with limited clinical differentiation.
- Generic-entry phase: Rapid price compression and brand-volume loss.
- Commodity phase: Low prices, fragmented suppliers and margin dependent on scale.
- Late-market phase: Revenue becomes sensitive to shortages, contracts and manufacturing efficiency.
Novartis, the historical commercial owner associated with Lotrel, reports financial results at business-unit and portfolio levels rather than providing a current standalone Lotrel revenue line in its principal public filings.[5] Public disclosures therefore do not support a reliable current product-level revenue estimate.
Revenue exposure
| Stakeholder |
Current exposure |
| Original brand owner |
Low direct exposure unless brand sales remain in a niche channel |
| Generic manufacturers |
Volume exposure with low per-tablet pricing |
| Wholesalers |
Transaction-volume exposure |
| Pharmacies |
Dispensing-margin and reimbursement exposure |
| Payers |
Savings from generic substitution |
| Patients |
Lower out-of-pocket cost, subject to formulary design |
| Contract manufacturers |
Potential volume opportunity, limited pricing power |
The product’s absolute revenue has likely fallen sharply from its branded period, while prescription demand remains supported by the prevalence of hypertension and long-term treatment duration. The category is therefore commercially durable but financially mature.
How does amlodipine/benazepril compare with competing antihypertensive combinations?
Amlodipine/benazepril competes with other two-drug regimens, including amlodipine/angiotensin-receptor blocker combinations, ACE inhibitor/thiazide combinations and single-pill products containing other calcium-channel blockers.
| Combination |
Competitive position |
| Amlodipine/benazepril |
Established, low-cost ACE inhibitor plus calcium-channel blocker |
| Amlodipine/valsartan |
Strong alternative where ACE-inhibitor cough is a concern |
| Amlodipine/losartan |
Generic, widely available ARB-based alternative |
| Lisinopril/hydrochlorothiazide |
Broadly used, inexpensive and familiar |
| Amlodipine monotherapy |
Lower pill burden and lower acquisition cost |
| Benazepril monotherapy |
Used where ACE inhibition is the primary treatment choice |
The main clinical disadvantage of benazepril relative to an ARB is the ACE-inhibitor adverse-effect profile, particularly cough and the risk of angioedema. The main commercial advantage is low generic cost and long clinical familiarity.
What licensing deals affect amlodipine/benazepril?
No current high-value licensing transaction is central to the commercial outlook for the standard U.S. product. The product’s active ingredients and ordinary tablet presentation are widely available through generic manufacturing and supply arrangements.
Historical commercialization, development and manufacturing agreements may exist in corporate archives, but they are unlikely to support a current exclusivity premium. For a transaction involving a specific generic supplier, the material contracts would more likely include:
- ANDA ownership or transfer.
- Authorized-generic supply.
- Contract manufacturing.
- API sourcing.
- Distribution and wholesaler agreements.
- Product liability allocation.
- Quality and recall obligations.
Those agreements are generally company-specific and are not captured fully in public FDA records.
What is the geographic market outlook?
The product has broad global utility because hypertension is prevalent and oral combination therapy is standard in many treatment guidelines. Commercial conditions differ substantially by jurisdiction.
| Region |
Market dynamic |
| United States |
Mature ANDA market, intense price competition |
| European Union |
National reimbursement and tender pressure |
| Emerging markets |
Higher volume potential, lower prices and variable regulatory enforcement |
| Japan |
Local approval and reimbursement requirements |
| Middle East and Africa |
Distributor-driven access and uneven generic penetration |
In the United States, the principal barriers are manufacturing economics, FDA compliance, supply continuity and channel access. In lower-income markets, registration, local distribution and price may matter more than patent position because core patent protection has expired.
How strong is the patent estate for amlodipine/benazepril?
The patent estate is weak from a current exclusivity perspective.
| Strength factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Broad combination protection |
Historical, not a current market barrier |
| Formulation protection |
Potentially narrow |
| Method-of-use protection |
Limited for established hypertension use |
| Manufacturing patents |
Supplier-specific and design-around risk |
| Regulatory exclusivity |
Expired |
| Biosimilar protection |
Not relevant |
| Generic-entry barrier |
Low |
The product can generate durable demand, but demand durability should not be confused with patent strength.
Key Takeaways
- Amlodipine besylate/benazepril hydrochloride is a mature fixed-dose antihypertensive combination.
- Lotrel has no meaningful current U.S. exclusivity position.
- Generic competition, not patent protection, determines pricing and market share.
- The product is not subject to biosimilar competition; ANDA-based generic competition is the relevant pathway.
- Historical patents may matter for diligence, but broad composition and combination protection have expired.
- Public filings do not provide a reliable current standalone revenue figure for Lotrel.
- Financial value is concentrated in high-volume, low-margin generic supply.
- The principal barriers to entry are manufacturing cost, FDA compliance, channel access and supply reliability.
- A new entrant’s upside depends more on shortage conditions and contracting than on intellectual property.
- The category has stable underlying demand but limited revenue-growth potential.
FAQs About Amlodipine Besylate and Benazepril Hydrochloride
Is Lotrel still sold in the United States?
Yes. Lotrel and generic amlodipine/benazepril products may be available, although product availability and manufacturer participation can change by strength and channel.
Is amlodipine/benazepril a generic drug?
The active combination is available as a generic. Lotrel is the historical branded reference product.
Can a generic manufacturer obtain exclusivity for amlodipine/benazepril?
A new generic may receive limited statutory exclusivity in specific circumstances, such as a qualifying first Paragraph IV approval. That does not restore broad product exclusivity after the historical patents have expired.
Does amlodipine/benazepril have a future as a branded product?
A broad branded relaunch would face substantial economic pressure from low-cost generic alternatives. A branded opportunity would require differentiated contracting, distribution, adherence support or a new formulation.
What is the biggest investment risk in this product category?
The main risk is margin compression. Prescription demand is relatively durable, but several generic suppliers can compete for the same volume, leaving little room for price increases outside periods of supply disruption.
References
- U.S. Food and Drug Administration. (n.d.). Lotrel: Amlodipine besylate and benazepril hydrochloride prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Courts. (n.d.). PACER case locator. https://pcl.uscourts.gov/
- U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and patent certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
- Novartis AG. (2024). Annual report 2023. https://www.novartis.com/investors/financial-data/annual-report-selector-selector-comparative-analyser
